Bio-Techne Q3 2024 Earnings Report
Key Takeaways
Bio-Techne reported a 3% increase in revenue to $303.4 million, with organic revenue growth of 2%. GAAP EPS was $0.31, while adjusted EPS reached $0.48. The Diagnostics & Genomics segment demonstrated strong growth, with 10% organic segment growth. Cash flow from operations increased by 31% to $223.5 million.
Organic revenue increased by 2% (3% reported) to $303.4 million.
GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago, with adjusted EPS of $0.48 compared to $0.53 one year ago.
Diagnostics & Genomics segment led to 10% organic segment growth (16% reported).
Cash flow generated from operations increased to $223.5 million, a 31% increase from the prior year.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Forward Guidance
No forward guidance was provided in the earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income